Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$48.6 million.

  • Celldex Therapeutics' Cash from Operations rose 1216.55% to -$48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$179.5 million, marking a year-over-year decrease of 1372.83%. This contributed to the annual value of -$157.8 million for FY2024, which is 4707.66% down from last year.
  • Latest data reveals that Celldex Therapeutics reported Cash from Operations of -$48.6 million as of Q3 2025, which was up 1216.55% from -$44.0 million recorded in Q2 2025.
  • Over the past 5 years, Celldex Therapeutics' Cash from Operations peaked at -$11.9 million during Q2 2021, and registered a low of -$55.3 million during Q3 2024.
  • Over the past 5 years, Celldex Therapeutics' median Cash from Operations value was -$28.6 million (recorded in 2023), while the average stood at -$30.4 million.
  • In the last 5 years, Celldex Therapeutics' Cash from Operations surged by 4603.03% in 2023 and then tumbled by 19135.47% in 2024.
  • Over the past 5 years, Celldex Therapeutics' Cash from Operations (Quarter) stood at -$14.5 million in 2021, then tumbled by 49.85% to -$21.8 million in 2022, then crashed by 49.49% to -$32.5 million in 2023, then increased by 0.11% to -$32.5 million in 2024, then crashed by 49.56% to -$48.6 million in 2025.
  • Its Cash from Operations stands at -$48.6 million for Q3 2025, versus -$44.0 million for Q2 2025 and -$54.4 million for Q1 2025.